Related Experiment Video
Updated: May 21, 2026
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
CD161⁺ NKT Cell Proportion as a Predictive Biomarker for Bortezomib Treatment Response in Newly Diagnosed Multiple
Background:
Multiple myeloma (MM) remains incurable, with drug resistance being a key clinical challenge. Impaired natural killer T (NKT) cell function may contribute to MM immune escape, while the significance of the inhibitory receptor CD161 expression on NKT cells is unclear. This study investigated the association between the peripheral blood CD3⁺CD56⁺CD161⁺ NKT cell proportion and response to bortezomib plus dexamethasone therapy in newly diagnosed MM (NDMM) patients.
Methods:
Seventy-two NDMM patients receiving bortezomib plus dexamethasone and 37 healthy controls (HCs) were enrolled. Flow cytometry assessed the peripheral blood CD3⁺CD56⁺CD161⁺ cell proportion before and after treatment. Treatment response was evaluated according to IMWG criteria (responders: ≥ partial response [PR]; non-responders: ≤ stable disease [SD]). Receiver operating characteristic (ROC) curve analysis evaluated predictive value. Correlation with clinical parameters (ISS stage, LDH, β₂-MG, etc.) was analyzed.
Results:
The baseline CD3⁺CD56⁺CD161⁺ proportion was significantly lower in NDMM patients than in HCs (2.25% vs. 4.20%, p < 0.05). After treatment, it increased to 3.10% (p < 0.05). Responders had a significantly higher baseline proportion than non-responders (3.40% vs. 1.60%, p < 0.0001). ROC analysis showed the baseline proportion predicted treatment response with an AUC of 0.789 (95% CI: 0.675 - 0.903). At the optimal cutoff of 1.85%, sensitivity was 87.9% and specificity was 71.8%. Patients with low proportions (< 1.85%) had a higher frequency of ISS stage III (p < 0.05) and significantly elevated LDH and β₂-MG levels (both p < 0.05).
Conclusions:
Low expression of peripheral blood CD3⁺CD56⁺CD161⁺ NKT cells is associated with increased tumor burden and bortezomib resistance in NDMM, suggesting its potential as a predictive biomarker for treatment response.
Insights
Low levels of CD3+CD56+CD161+ natural killer T (NKT) cells in newly diagnosed multiple myeloma (NDMM) patients indicate resistance to bortezomib and dexamethasone therapy. This finding suggests NKT cell proportion is a potential biomarker for treatment response.
Area of Science:
- Immunology
- Hematology
- Oncology
Background:
- Multiple myeloma (MM) is an incurable blood cancer characterized by drug resistance.
- Impaired natural killer T (NKT) cell function may facilitate immune evasion in MM.
- The role of the inhibitory receptor CD161 on NKT cells in MM is not well understood.
Purpose of the Study:
- To investigate the association between the proportion of peripheral blood CD3+CD56+CD161+ NKT cells and treatment response in newly diagnosed multiple myeloma (NDMM) patients.
- To evaluate the predictive value of CD3+CD56+CD161+ NKT cell levels for bortezomib plus dexamethasone therapy outcomes.
- To explore the correlation between CD3+CD56+CD161+ NKT cell proportion and clinical parameters in NDMM.
Main Methods:
- Flow cytometry was used to quantify peripheral blood CD3+CD56+CD161+ NKT cells in 72 NDMM patients and 37 healthy controls (HCs) before and after treatment.
- Treatment response was assessed using International Myeloma Working Group (IMWG) criteria.
- Receiver operating characteristic (ROC) curve analysis and correlation analyses with clinical parameters (ISS stage, LDH, β₂-MG) were performed.
Main Results:
- NDMM patients had significantly lower baseline CD3+CD56+CD161+ NKT cell proportions compared to HCs (2.25% vs. 4.20%, p < 0.05).
- Responders exhibited a higher baseline proportion (3.40%) than non-responders (1.60%, p < 0.0001), with ROC analysis yielding an AUC of 0.789.
- Low baseline proportions (< 1.85%) were associated with advanced ISS stage, elevated LDH, and β₂-MG levels, indicating increased tumor burden.
Conclusions:
- Reduced peripheral blood CD3+CD56+CD161+ NKT cell expression is linked to higher tumor burden and resistance to bortezomib in NDMM.
- The proportion of CD3+CD56+CD161+ NKT cells may serve as a predictive biomarker for treatment response in NDMM patients.
- Further research could elucidate the mechanisms underlying NKT cell dysfunction in MM and its impact on therapeutic outcomes.
